This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kitada, S. Articles by Kobayashi, K. Search for Related Content PubMed PubMed Citation Articles by Kitada, S. Articles by Kobayashi, K.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, January 2005, p. 44-51, Vol. 12, No. 1
1071-412X/05/$08.00+0     doi:10.1128/CDLI.12.1.44-51.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Use of Glycopeptidolipid Core Antigen for Serodiagnosis of Mycobacterium avium Complex Pulmonary Disease in Immunocompetent Patients

Seigo Kitada,^1,2* Ryoji Maekura,^2,3 Naomi Toyoshima,³ Takashi Naka,¹ Nagatoshi Fujiwara,¹ Masami Kobayashi,³ Ikuya Yano,⁴ Masami Ito,² and Kazuo Kobayashi¹

Department of Host Defense, Osaka City University Graduate School of Medicine, Abeno-ku,¹ Toneyama Institute for Tuberculosis Research, Toyonaka-shi,³ Department of Internal Medicine, Toneyama National Hospital, Toyonaka-shi, Osaka,² Japan BCG Laboratory, Kiyose-shi, Tokyo, Japan⁴

Received 6 February 2004/ Returned for modification 20 May 2004/ Accepted 6 October 2004

We report the development of a serodiagnostic method for Mycobacterium avium complex (MAC) disease with an enzyme immunoassay (EIA) with the MAC-specific glycopeptidolipid (GPL) core as the antigen. In this study, we confirmed by EIA that the GPL core antibody was in the sera of immunocompetent patients with MAC disease. The EIA for quantifying the GPL core antibody was evaluated as a clinical tool for serodiagnosis of pulmonary MAC disease. A significant increase in GPL core antibodies (immunoglobulins G, A, and M) was detected in sera of patients with MAC pulmonary diseases when they were compared to patients who were colonized with MAC, patients with Mycobacterium kansasii disease or tuberculosis, and healthy subjects. The sensitivities and specificities of the GPL core-based EIA for diagnosis of MAC pulmonary disease were 72.6% and 92.2%, respectively, for IgG, 92.5% and 95.1%, respectively, for IgA, and 78.3% and 91.0%, respectively, for IgM. The best sensitivity and specificity were obtained by measuring immunoglobulin A antibodies against GPL core antigen. The level of GPL core antibodies reflected disease activity, since it decreased in cured MAC patients who had responded to chemotherapy. Measurement of serum antibodies against GPL core is useful for both diagnosis and assessment of disease activity in MAC disease of the lung.

---

* Corresponding author. Mailing address: Department of Internal Medicine, Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka-shi, Osaka 560-8552, Japan. Phone: 81-6-6853-2001. Fax: 81-6-6853-3127. E-mail: kitadas{at}toneyama.hosp.go.jp.

---

Clinical and Diagnostic Laboratory Immunology, January 2005, p. 44-51, Vol. 12, No. 1
1071-412X/05/$08.00+0     doi:10.1128/CDLI.12.1.44-51.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Fujita, Y., Doi, T., Maekura, R., Ito, M., Yano, I. (2006). Differences in serological responses to specific glycopeptidolipid-core and common lipid antigens in patients with pulmonary disease due to Mycobacterium tuberculosis and Mycobacterium avium complex. J Med Microbiol 55: 189-199 [Abstract] [Full Text]  
• Fujita, Y., Doi, T., Sato, K., Yano, I. (2005). Diverse humoral immune responses and changes in IgG antibody levels against mycobacterial lipid antigens in active tuberculosis. Microbiology 151: 2065-2074 [Abstract] [Full Text]